Treatment of autosomal dominant hearing loss by in vivo delivery of genome editing agents.
about
Non-viral delivery systems for CRISPR/Cas9-based genome editing: Challenges and opportunities.Identification of four TMC1 variations in different Chinese families with hereditary hearing loss.Osteogenesis imperfecta and therapeutics.In vivo base editing of post-mitotic sensory cells.Cochlear Gene Therapy for Sensorineural Hearing Loss: Current Status and Major Remaining Hurdles for Translational Success.Age-associated decline in Nrf2 signaling and associated mtDNA damage may be involved in the degeneration of the auditory cortex: Implications for central presbycusisHigh-throughput in vivo screen of functional mRNA delivery identifies nanoparticles for endothelial cell gene editingOutlook and future of inner ear therapyTranscription factor induced conversion of human fibroblasts towards the hair cell lineageBlossom of CRISPR technologies and applications in disease treatmentGene Therapy in Mouse Models of Deafness and Balance DysfunctionDifferentiation and transplantation of human induced pluripotent stem cell-derived otic epithelial progenitors in mouse cochleaCRISPR-delivery particles targeting nuclear receptor-interacting protein 1 () in adipose cells to enhance energy expenditureIn vivo CRISPR editing with no detectable genome-wide off-target mutationsTargeting fidelity of adenine and cytosine base editors in mouse embryos
P2860
Q52431943-D5562D6A-EBA2-44CB-A92B-0A70EE7D36B1Q52588849-F1BCC1E8-09AB-4924-B339-E4919E1F64D0Q52655586-886332EB-0609-498E-A77F-E9889892D7C4Q55030452-B464FAC0-7385-4E4A-8BB0-EFB3FC220EDCQ55657184-4E5CEFFB-089B-483E-B852-98B3C241A217Q57056144-F7FE480F-2E53-49EF-AC0D-2B5FFAF1E162Q57061947-E3B73756-F3FD-4912-AF47-65C12F9877CCQ57139394-C32C60AE-EA0E-454F-B239-B91DF12E89C8Q57176993-A573851D-1324-4CED-9542-127A3F7C1CD4Q58120494-EB59DBE8-955E-4390-A227-D4061FD60AEAQ58694271-10929D40-739F-4A0B-B919-10FFA7B82B92Q58695043-3D943833-E3EF-4BAF-A158-B2BCD231B997Q58760448-7F862524-309C-4A74-9AE9-0EBD93DBB8A2Q59060174-E1213C9E-1778-488B-B08A-3A19F2C1CE4DQ59129098-2B6A3821-A58E-4DEA-BE4B-5ED786922121
P2860
Treatment of autosomal dominant hearing loss by in vivo delivery of genome editing agents.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Treatment of autosomal dominan ...... very of genome editing agents.
@en
Treatment of autosomal dominan ...... very of genome editing agents.
@nl
type
label
Treatment of autosomal dominan ...... very of genome editing agents.
@en
Treatment of autosomal dominan ...... very of genome editing agents.
@nl
prefLabel
Treatment of autosomal dominan ...... very of genome editing agents.
@en
Treatment of autosomal dominan ...... very of genome editing agents.
@nl
P2093
P2860
P50
P356
P1433
P1476
Treatment of autosomal dominant hearing loss by in vivo delivery of genome editing agents
@en
P2093
Bifeng Pan
David B Thompson
David R Liu
Hongyang Wang
Jeffrey R Holt
Johnny H Hu
M Charles Liberman
Mingqian Huang
Qiaobing Xu
Shiming Yang
P2860
P2888
P304
P356
10.1038/NATURE25164
P407
P577
2017-12-20T00:00:00Z